51
|
Dorizy-Vuong V, Chambon R, Berrouet L, Pinton F, Layan A, Gauthier-Lucas E, Doutre MS, Joseph JP, Beylot-Barry M, Taïeb A. SmartDerm : mise en place de la télé-expertise dermatologique dans trois départements en déprise médicale de Nouvelle-Aquitaine. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
52
|
Marescassier H, Dousset L, Hainaut E, Bedane C, Vaillant L, Celerier P, Beylot-Barry M, Masson Regnault M. Facteurs prédictifs de non réponse au vismodégib dans les carcinomes basocellulaires localement avancés. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
53
|
Canu D, Lamoureux A, Gérard E, Ouhabrache N, Beylot-Barry M. Radiothérapie de basse énergie et mélanome de Dubreuilh : étude rétrospective monocentrique de 91 patients. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
54
|
Canu D, Pham-Ledard A, Ouhabrache N, Beylot-Barry M. Évolution des modalités de l’électronthérapie corporelle totale dans le mycosis fongoïde : étude monocentrique. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
55
|
Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Ingen-Housz-Oro S, Battistella M, d'Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereure O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M. Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry. Br J Dermatol 2020; 184:1059-1067. [PMID: 33131055 DOI: 10.1111/bjd.19644] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Primary cutaneous lymphomas (PCLs) are a heterogeneous group of T-cell (CTCL) and B-cell (CBCL) malignancies. Little is known about their epidemiology at initial presentation in Europe and about potential changes over time. OBJECTIVES The aim of this retrospective study was to analyse the frequency of PCLs in the French Cutaneous Lymphoma Registry (GFELC) and to describe the demography of patients. METHODS Patients with a centrally validated diagnosis of primary PCL, diagnosed between 2005 and 2019, were included. RESULTS The calculated incidence was unprecedently high at 1·06 per 100 000 person-years. The number of included patients increased yearly. Most PCL subtypes were more frequent in male patients, diagnosed at a median age of 60 years. The relative frequency of rare CTCL remained stable, the proportion of classical mycosis fungoides (MF) decreased, and the frequency of its variants (e.g. folliculotropic MF) increased. Similar patterns were observed for CBCL; for example, the proportion of marginal-zone CBCL increased over time. CONCLUSIONS Changes in PCL frequencies may be explained by the emergence of new diagnostic criteria and better description of the entities in the most recent PCL classification. Moreover, we propose that an algorithm should be developed to confirm the diagnosis of PCL by central validation of the cases.
Collapse
|
56
|
Barailler H, Dousset L, Mertens C, Maurel A, Gérard E, Prey S, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Impact sur la qualité de vie et l’autonomie des patients de plus de 75 ans traités par anti-PD-1 pour un mélanome métastatique : étude prospective monocentrique. Ann Dermatol Venereol 2020; 147:713-720. [DOI: 10.1016/j.annder.2020.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 06/26/2020] [Accepted: 07/17/2020] [Indexed: 10/23/2022]
|
57
|
D'Incan M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, Grange F, Quereux G, Templier I, Ram-Wolff C, Adamski H, Lambert C, Descours C. Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. Br J Dermatol 2020; 184:356-358. [PMID: 32810288 DOI: 10.1111/bjd.19495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 07/30/2020] [Accepted: 08/14/2020] [Indexed: 11/28/2022]
|
58
|
Le Cleach L, Dousset L, Assier H, Fourati S, Barbarot S, Boulard C, Bourseau Quetier C, Cambon L, Cazanave C, Colin A, Kostrzewa E, Lesort C, Levy Roy A, Lombart F, Marco-Bonnet J, Monfort JB, Samimi M, Tardieu M, Wolkenstein P, Sbidian E, Beylot-Barry M. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. Br J Dermatol 2020; 183:866-874. [PMID: 32628270 PMCID: PMC7361395 DOI: 10.1111/bjd.19377] [Citation(s) in RCA: 54] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/26/2020] [Indexed: 01/21/2023]
Abstract
Background Acral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID‐19. In more than 80% of patients tested, nasopharyngeal swabs were negative on reverse transcription polymerase chain reaction (RT‐PCR) for SARS‐CoV‐2 when performed, and serology was generally not performed. Methods A national survey was launched on 30 March 2020 by the French Society of Dermatology asking physicians to report cases of skin manifestations in patients with suspected or confirmed COVID‐19 by using a standardized questionnaire. We report the results for acral manifestations. Results We collected 311 cases of acral manifestations [58.5% women, median age 25.7 years (range 18–39)]. The most frequent clinical presentation (65%) was typical chilblains. In total, 93 cases (30%) showed clinical suspicion of COVID‐19, 67 (22%) had only less specific infectious symptoms and 151 (49%) had no clinical signs preceding or during the course of acral lesions. Histology of skin biopsies was consistent with chilblains. Overall, 12 patients showed significant immunological abnormalities. Of the 150 (48%) patients who were tested, 10 patients were positive. Seven of 121 (6%) RT‐PCR‐tested patients were positive for SARS‐CoV‐2, and five of 75 (7%) serology‐tested patients had IgG anti‐SARS‐CoV‐2. Tested/untested patients or those with/without confirmed COVID‐19 did not differ in age, sex, history or acral lesion clinical characteristics. Conclusions The results of this survey do not rule out that SARS‐CoV‐2 could be directly responsible for some cases of chilblains, but we found no evidence of SARS‐CoV‐2 infection in the large majority of patients with acral lesions during the COVID‐19 lockdown period in France. What is already known about this topic? About 1000 cases of acral lesions, mainly chilblains, were reported during the COVID‐19 outbreak. Chilblains were reported to occur in young people within 2 weeks of infectious signs, which were mild when present. Most cases did not have COVID‐19 confirmed by reverse transcription polymerase chain reaction (RT‐PCR), and few serology results were available.
What does this study add? Among 311 patients with acral lesions, mainly chilblains, during the COVID‐19 lockdown period in France, the majority of patients tested had no evidence of SARS‐CoV‐2 infection. Overall, 70 of 75 patients were seronegative for SARS‐Cov‐2 serology and 114 of 121 patients were negative for SARS‐CoV‐2 RT‐PCR.
Collapse
|
59
|
Matar S, Oulès B, Sohier P, Chosidow O, Beylot-Barry M, Dupin N, Aractingi S. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol 2020; 34:e686-e689. [PMID: 32589293 PMCID: PMC7361331 DOI: 10.1111/jdv.16775] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 06/16/2020] [Indexed: 01/08/2023]
|
60
|
Villani AP, Amatore F, Tauber M, Guillot B, Viguier M, Beylot-Barry M, Jullien D. Impact of the French guidelines on the prescribing habits of systemic treatments for moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2020; 34:e747-e748. [PMID: 32396980 DOI: 10.1111/jdv.16601] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 04/30/2020] [Indexed: 11/28/2022]
|
61
|
Berard E, Barnetche T, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T, Kostine M. SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Description and initial management of rheumatic immune-related adverse-events (irAEs) from cancer immunotherapies have been reported by several groups but to date, few studies have evaluated the long-term outcomes and management of rheumatic irAEs (1).Objectives:To describe the long-term management and assess the one-year outcomes of patients who experienced rheumatic immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI).Methods:This was a single-centre prospective observational study including patients referred for musculoskeletal symptoms while treated with ICI. After baseline rheumatological evaluation defining the clinical entity presented, follow-up visits were organised according to the type and severity of irAE. At one year, persistence of irAE, ongoing treatment, as well as cancer outcomes were assessed.Results:63 patients were included between September 2015 and June 2018. 24 patients (38%) presented with non-inflammatory musculoskeletal conditions managed with short-term symptomatic treatment and did not require specific follow-up. 39 patients (62%) experienced inflammatory manifestations, mimicking either rheumatoid arthritis (RA, n=19), polymyalgia rheumatica (PMR, n=16), psoriatic arthritis (PsA, n=3) and one flare of a preexisting axial spondyloarthritis. Overall, 32 patients (82%) received systemic glucocorticoids, with a median rheumatic dosage of 15mg/day (range: 5-60mg/day). None of the patients had to permanently discontinue ICI therapy for rheumatic irAE. 20 patients (67%) were still receiving glucocorticoids at one year, with a median dosage of 5mg/day (range: 2-20mg/day). Glucocorticoids were more frequently discontinued for patients with RA-like condition (44%) than PMR-like condition (23%), but no other predictive factor of glucocorticoids withdrawal could be identified. At one year, overall survival and progression-free survival were comparable between patients who were still receiving glucocorticoids for rheumatic irAE and patients who have discontinued. Eight patients required csDMARDs.Conclusion:At one year, a majority of patients required long-term low-dose glucocorticoids for chronic rheumatic irAE, which seems not altering oncological control.References:[1]Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2019 Sep 20.Disclosure of Interests:None declared
Collapse
|
62
|
Malmontet T, Dousset L, Gerard E, Ouhabrache N, Pham-Ledard A, Beylot-Barry M. [Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma]. Ann Dermatol Venereol 2019; 147:228-232. [PMID: 31791649 DOI: 10.1016/j.annder.2019.08.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 07/07/2019] [Accepted: 08/22/2019] [Indexed: 01/27/2023]
Abstract
INTRODUCTION Vismodégib is the first-line treatment for non-operable or metastatic locally advanced basal cell carcinomas (LABCC), although complete response is rare and adverse effects are common. Immune checkpoint inhibitors are currently being evaluated in this indication. Herein we report a case of LABCC that responded dramatically to sequenced "immunotherapy then radiotherapy". OBSERVATION A 47-year-old male presented peri- and intra-orbital infiltrative LABCC that had been present for more than 10 years. After an initial response to vismodégib, further disease progression resulted in the introduction of successive lines of treatment (radiotherapy, platinum salts and itraconazole) without any significant response. Compassionate treatment with pembrolizumab was initiated. After eight courses, major clinical progression occurred with intraoral extension responsible for respiratory discomfort. Following withdrawal of pembrolizumab, high-energy radiotherapy was started with a spectacular response, both clinically and in terms of imaging. DISCUSSION The efficacy of "radiotherapy-immunotherapy" sequencing in melanoma has been reported, due in particular to the abscopal effect and radiosensitisation. In our case, where the sequence was inverted, immunotherapy may have enhanced the effects of radiotherapy through "immunosensitisation", whereas radiotherapy alone had previously been ineffective. This observation underlines the potential value of these treatments, either combined or in sequence, and their synergistic effects and optimal association require further evaluation.
Collapse
|
63
|
Maubec E, Boubaya M, Petrow P, Basset-Seguin N, Grob JJ, Dréno B, Beylot-Barry M, Scheer-Senyarich I, Helfen S, Deschamps L, Leccia MT, Stefan A, Saiag P, De Quatrebarbes J, Meyer N, Alloux C, Lopez I, Cherbal S, Tibi A, Levy V. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
64
|
Goiset A, Milpied B, Marti A, Marie J, Leroy-Colavolpe V, Pham-Ledard A, Foulet F, Oro S, Hemery F, Chosidow O, Beylot-Barry M. Caractéristiques, pathologies associées et prise en charge des intertrigo inter-orteils à bacille Gram-négatif: étude rétrospective de 62 patients. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
65
|
Bourlond F, Battistella M, Dousset L, Amici JM, Tuzin N, Vergier B, Beylot-Barry M, Cribier B. Étude clinique de 62 trichoblastomes et comparaison au carcinome basocellulaire nodulaire. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
66
|
Costedoat I, Pham-Ledard A, Doutre MS, Beylot-Barry M, Cogrel O. Lupus discoïde du bras en regard d’un implant contraceptif à base de progestérone. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
67
|
Sonigo G, Battistella M, Beylot-Barry M, Oro S, Franck N, Barete S, Boulinguez S, Dereure O, Bonnet N, Socié G, Brice P, Boccara O, Bodemer C, Adamski H, D’Incan M, Ortonne N, Fraitag S, Brunet-Possenti F, Dalle S, Suarez F, Marcais A, Skowron F, Haidar D, Maubec E, Bohelay G, Laroche L, Mahé A, Birckel E, Bouaziz JD, Brocheriou I, Dubois R, Faiz S, Fadlallah J, Ram-Wolff C, Carlotti A, Bens G, Balme B, Vergier B, Laurent-Roussel S, Deschamps L, Carpentier O, Moguelet P, Hervé G, Comoz F, Le Gall F, Leverger G, Finon A, Augereau O, Bléchet C, Kerdraon R, lamant L, Tournier E, Franck F, Costes-Martineau V, Szablewski V, Taix S, Beschet I, Guérin F, Sepulveda F, Bagot M, De Saint-Basile G, Michonneau D, De Masson A. Étude clinique à long terme et mutations HAVCR2 chez 70 patients atteints de lymphome T sous cutané à type de panniculite. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
68
|
Dangien A, Beylot-Barry M, Battistella M, Ram-Wolff C, Talbot A, Rybojad M, Vergier B, Jachiet M, Bouaziz JD, Arnulf B, Bagot M, De Masson A. Association lymphome B cutané primitif de la zone marginale et amyloses cutanées. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
69
|
Valentin J, Ferté T, Dorizy-Vuong V, Dousset L, Dutriaux C, Prey S, Pham-Ledard A, Beylot-Barry M, Gérard E. Survie des patients traités pour un mélanome métastatique après arrêt de l’immunothérapie pour réponse objective ou toxicité : étude rétrospective de cohorte. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
70
|
Bergqvist C, Beylot-Barry M, Ram-Wolff C, Bagot M, Adamski H, Le Corre Y, Bonnet N, Vivard-Wallee I, Polat A, Dereure O, Brunet-Possenti F, Ortonne N, Oro S. Papuloses lymphomatoïdes de type D et E: série multicentrique de 21 patients. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
71
|
Pham AD, Guillot B, Beylot-Barry M, Chosidow O, Reygagne P, Joly P. Réponse des auteurs à la correspondance à propos de l’article : « Place de l’Androcur® dans le traitement de l’alopécie féminine diffuse ». Ann Dermatol Venereol 2019; 146:822-823. [DOI: 10.1016/j.annder.2019.10.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
72
|
Legrand A, Heron-Mermin D, Pham-Ledard A, Beylot-Barry M, Cogrel O. Lymphœdème ano-génital et hidradénite suppurée : 6 cas. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
73
|
Nicoletis I, Cogrel O, Mascitti H, Leroy-Colavolpe V, Benzaquen M, Beylot-Barry M, Samimi M. Formation à la chirurgie au cours de l’internat de dermatologie en France : enquête auprès des jeunes dermatologues. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
74
|
Barailler H, Dousset L, Mertens C, Gerard E, Prey S, Dutriaux C, Beylot-Barry M, Pham-Ledard A. Étude prospective sur une série de patients ≥ 75 ans traités par anti-PD-1 pour un mélanome métastatique: impact sur l’autonomie et la qualité de vie. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
75
|
Mignard C, Maho-Vaillant M, Prost-Squarcioni C, Calbo S, Golinski ML, Labeille B, Picard-Dahan C, Konstantinou M, Richard MA, Bouaziz J, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Martin L, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Hébert V, Joly P. Facteurs pronostiques de rechute à long terme chez les patients atteints de pemphigus traités par rituximab en première ligne. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|